Best Peptides for Weight Loss
Evidence-based peptides researched for weight management, appetite control, and metabolic health including FDA-approved options.
Understanding Weight Loss Peptides
Weight loss peptides represent one of the most clinically validated areas of peptide research. GLP-1 receptor agonists like Semaglutide and Tirzepatide have revolutionized obesity treatment, with clinical trials showing average weight loss of 15-25% body weight. These medications work by mimicking hormones that regulate appetite, blood sugar, and metabolism. Newer compounds like Retatrutide (a triple agonist) are showing even more impressive results in ongoing trials.
Key Considerations
- FDA-approved options (Semaglutide, Tirzepatide) should be first-line considerations
- GI side effects are common during dose titration
- Long-term commitment is typically needed - weight regain common after discontinuation
- Medical supervision is essential for prescription peptides
- Lifestyle modifications enhance results significantly
FDA Approved Options (7)
Semaglutide
Also: Ozempic, Wegovy, Rybelsus
A GLP-1 receptor agonist with multiple FDA approvals including weight loss, T2D, CV risk reduction, and kidney protection. Wegovy pill approved Dec 2025 as first oral GLP-1 for weight loss.
Tirzepatide
Also: Mounjaro, Zepbound, LY3298176
A dual GIP/GLP-1 receptor agonist representing the next generation of incretin-based therapies. Shows superior weight loss compared to semaglutide in head-to-head trials. First medication approved for obstructive sleep apnea.
Liraglutide
Also: Victoza, Saxenda
An FDA-approved GLP-1 receptor agonist for type 2 diabetes and chronic weight management. The predecessor to semaglutide with daily dosing.
Dulaglutide
Also: Trulicity
An FDA-approved weekly GLP-1 receptor agonist for type 2 diabetes. Fused to an Fc antibody fragment for extended duration of action.
Exenatide
Also: Byetta, Bydureon, Exendin-4
The first GLP-1 receptor agonist approved for diabetes. Derived from Gila monster saliva. Available in twice-daily and weekly formulations.
Semaglutide Oral
Also: Rybelsus
The oral formulation of semaglutide using SNAC absorption enhancer. First oral GLP-1 receptor agonist FDA approved.
Setmelanotide
Also: Imcivree, RM-493
An MC4R agonist for rare genetic obesity disorders. FDA approved for specific gene mutations causing obesity.
Research Peptides (8)
These peptides are being researched but are not FDA approved. They should only be considered for research purposes or under medical supervision.
Retatrutide
Clinical TrialsA triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 3 trials show up to 28.7% weight loss (71 lbs average), the highest of any obesity drug. Expected FDA approval late 2026 to early 2027.
Survodutide
Clinical TrialsA dual GLP-1/glucagon receptor agonist in development for obesity and MASH. Has FDA Breakthrough Therapy Designation for MASH with fibrosis.
Orforglipron
Clinical TrialsAn oral non-peptide GLP-1 receptor agonist. NDA under FDA review with decision expected April 10, 2026. If approved, will compete directly with oral Wegovy.
CagriSema
Clinical TrialsA combination of semaglutide and cagrilintide (amylin analog). The most effective weight loss drug candidate, showing 22.7% body weight reduction in Phase 3 trials - superior to any single-agent GLP-1.
5-Amino-1MQ
PreclinicalA selective NNMT (nicotinamide N-methyltransferase) inhibitor that enhances cellular energy metabolism. Not a peptide but a small molecule research compound commonly used alongside peptides for fat loss and metabolic support.
Cagrilintide
Clinical TrialsA long-acting amylin analog developed by Novo Nordisk for obesity treatment. Works through a different mechanism than GLP-1 agonists, targeting amylin receptors in the brain to reduce appetite and slow gastric emptying. Shows enhanced weight loss when combined with semaglutide (CagriSema).
AOD-9604
Clinical TrialsA modified fragment of human growth hormone (amino acids 177-191) studied for fat metabolism effects without the broader hormonal effects of full GH.
HGH Fragment 176-191
Clinical TrialsThe lipolytic fragment of human growth hormone. Contains the fat-burning portion of HGH without effects on blood sugar or cell proliferation.
Frequently Asked Questions
What is the most effective peptide for weight loss?
Based on clinical trial data, Tirzepatide (Zepbound/Mounjaro) has shown the highest average weight loss at 20-25% body weight in studies. Semaglutide (Wegovy) shows 15-17% average weight loss. Both are FDA-approved and require a prescription.
How do GLP-1 peptides cause weight loss?
GLP-1 peptides reduce appetite by acting on brain hunger centers, slow gastric emptying so you feel full longer, improve insulin sensitivity, and may reduce food reward and cravings. The combined effect is significant calorie reduction without extreme hunger.
Are weight loss peptides safe?
FDA-approved weight loss peptides like Semaglutide and Tirzepatide have undergone extensive clinical trials. Common side effects include nausea, vomiting, and other GI symptoms, especially during titration. They carry warnings about thyroid tumors and pancreatitis. Always use under medical supervision.
Explore Other Goals
Compare Peptides Side-by-Side
Use our comparison tool to evaluate multiple peptides at once.